Palbociclib
Who holds supplier records for Palbociclib? 27 organisations hold a current record for Palbociclib: an active US FDA Type II Drug Master File. A further 1 organisation has only historical (inactive) DMF filings. Recorded organisation countries for current records: India (15), China (5), Netherlands (2), Canada (1) and 2 other countries (2); not recorded for 2.
Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records
Cite as: PharmaTek, “Palbociclib: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/palbociclib
Reading the evidence
- 27 current records
Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.
- Most recorded organisations are in India
15 of the 25 current records with a recorded country list India. Organisation country is not necessarily the manufacturing site.
- 15 with a company-level GMP certificate on record
These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.
- US product patents listed
The latest patent listed in the FDA Orange Book for an approved product containing Palbociclib expires 19 Feb 2037. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.
Current records (27)
Organisations holding an active US FDA Type II Drug Master File or a CEP for Palbociclib. Country is the organisation's recorded country, not necessarily the manufacturing site.
- AARTI PHARMALABS LIMITEDIndiaActive DMF 41388 · latest filing Apr 2025
- Alembic Pharmaceuticals LimitedIndia Company GMP cert on recordActive DMF 33123 · latest filing Sept 2018
- ALIVUS LIFE SCIENCES LTDIndia Company GMP cert on recordActive DMF 41602 · latest filing Mar 2025
- Anhui Haoyuan Pharmaceutical Co., Ltd.ChinaActive DMF 44240 · latest filing Jun 2026
- Apotex Inc.CanadaActive DMF 32907 · latest filing Jul 2018
- BIOPHORE INDIA PHARMACEUTICALS PRIVATE LIMITEDIndiaActive DMF 32867 · latest filing Aug 2018
- CDYMAX (INDIA) PHARMA PRIVATE LIMITEDIndia Company GMP cert on recordActive DMF 33055 · latest filing Aug 2018
- CHONGQING CARELIFE PHARMACEUTICAL CO LTDChinaActive DMF 36538 · latest filing Apr 2022
- CHUNGHWA CHEMICAL SYNTHESIS AND BIOTECH CO LTDCompany GMP cert on recordActive DMF 37586 · latest filing Nov 2022
- Dr. Reddy's Laboratories Ltd.India Company GMP cert on recordActive DMF 32646 · latest filing Mar 2018
- Hetero Labs LimitedIndia Company GMP cert on recordActive DMF 32273 · latest filing Mar 2018
- Intas Pharmaceuticals Ltd.India Company GMP cert on recordActive DMF 43679 · latest filing Feb 2026
- LEE FINE CHEM PRIVATE LIMITEDIndia Company GMP cert on recordActive DMF 44792 · latest filing Sept 2026
- LIANYUNGANG RUNZHONG PHARMACEUTICAL CO LTDChinaActive DMF 36417 · latest filing Dec 2021
- Macleods Pharmaceuticals Ltd.India Company GMP cert on recordActive DMF 43370 · latest filing Mar 2026
- MATRIX PHARMACORP PRIVATE LTDIndiaActive DMF 32294 · latest filing Dec 2017
- MSN Laboratories Private LimitedIndia Company GMP cert on recordActive DMF 32934 · latest filing Jul 2018
- SABA ILAC SANAYI VE TICARET ASActive DMF 43096 · latest filing Dec 2025
- SCINOPHARM TAIWAN LTDTaiwanActive DMF 32925 · latest filing Jul 2018
- Shandong Anhong Pharmaceutical Co., Ltd.China Company GMP cert on recordActive DMF 33057 · latest filing Aug 2018
- SHILPA PHARMA LIFESCIENCES LTDIndiaActive DMF 42794 · latest filing Oct 2025
- SHIVALIK RASAYAN LTDIndiaActive DMF 39372 · latest filing Jan 2024
- Sun Pharmaceutical Industries LimitedIndia Company GMP cert on recordActive DMF 33149 · latest filing Nov 2018
- SynthonNetherlands Company GMP cert on recordActive DMF 34761 · latest filing Apr 2020
- TAPI NL BVNetherlandsActive DMF 33006 · latest filing Oct 2018
- Zakłady Farmaceutyczne Polpharma S.A.Poland Company GMP cert on recordActive DMF 39559 · latest filing Apr 2024
- Zhejiang Ausun Pharmaceutical Co., Ltd.China Company GMP cert on recordActive DMF 40807 · latest filing Nov 2024
The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.
Historical records (1)
Organisations whose Type II DMFs for Palbociclib are no longer active. These show a past filing, not current supply.
Show all 1 historical record
- China · Inactive DMF 33297 · filed Nov 2018
US product patents and exclusivity
The FDA Orange Book lists patents and exclusivities for specific approved products (6 listed products contain Palbociclib). The latest listed patent expires 19 Feb 2037. The latest listed exclusivity runs to 24 Jun 2029. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.
Overview
Palbociclib is a selective cyclin-dependent kinase 4/6 (CDK4/6) inhibitor used in the treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. It works by interfering with the growth and division of cancer cells.
Chemical identity
- IUPAC name
- 6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-yl-2-pyridinyl)amino]pyrido[2,3-d]pyrimidin-7-one
- Canonical SMILES
- CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C
- InChIKey
- AHJRHEGDXFFMBM-UHFFFAOYSA-N
- Synonyms
- Ibrance API, ibrance, pd-0332991
Pharmacologic class
As the US FDA states it for this active substance on product listings.
- Established pharmacologic class
- Kinase Inhibitor
- Mechanism of action
- Cytochrome P450 3A Inhibitors; Kinase Inhibitors
Therapeutic areas
Record history
No change to the current records between 13 Nov 2026 and 16 Nov 2026.
Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week
What these records establish
- An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
- A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
- Historical records show a past filing, not current supply.
- Company GMP certificates are matched to the organisation, not to the site making this substance.
- A substance missing from these registers is not evidence that no supplier exists.
Frequently asked questions
Which organisations hold current supplier records for Palbociclib?
27 organisations hold an active US FDA Type II Drug Master File or a CEP for Palbociclib: AARTI PHARMALABS LIMITED (India), Alembic Pharmaceuticals Limited (India), ALIVUS LIFE SCIENCES LTD (India), Anhui Haoyuan Pharmaceutical Co., Ltd. (China), Apotex Inc. (Canada), BIOPHORE INDIA PHARMACEUTICALS PRIVATE LIMITED (India), CDYMAX (INDIA) PHARMA PRIVATE LIMITED (India) and CHONGQING CARELIFE PHARMACEUTICAL CO LTD (China), and 19 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.
Which Palbociclib Drug Master Files are active?
AARTI PHARMALABS LIMITED (DMF 41388), Alembic Pharmaceuticals Limited (DMF 33123), ALIVUS LIFE SCIENCES LTD (DMF 41602), Anhui Haoyuan Pharmaceutical Co., Ltd. (DMF 44240), Apotex Inc. (DMF 32907), BIOPHORE INDIA PHARMACEUTICALS PRIVATE LIMITED (DMF 32867), CDYMAX (INDIA) PHARMA PRIVATE LIMITED (DMF 33055) and CHONGQING CARELIFE PHARMACEUTICAL CO LTD (DMF 36538) and 19 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.
What do the historical Palbociclib records mean?
1 organisation has only inactive Type II DMFs for Palbociclib. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.
Does the FDA Orange Book list patents for products containing Palbociclib?
Yes. The latest patent listed for an approved US product containing Palbociclib expires 19 Feb 2037, across 6 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.
How do I qualify a Palbociclib supplier?
Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.
Do you supply Palbociclib?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.